HRP20130004T1 - 4-supstituirani derivati fenoksifeniloctene kiseline - Google Patents
4-supstituirani derivati fenoksifeniloctene kiseline Download PDFInfo
- Publication number
- HRP20130004T1 HRP20130004T1 HRP20130004TT HRP20130004T HRP20130004T1 HR P20130004 T1 HRP20130004 T1 HR P20130004T1 HR P20130004T T HRP20130004T T HR P20130004TT HR P20130004 T HRP20130004 T HR P20130004T HR P20130004 T1 HRP20130004 T1 HR P20130004T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- methyl
- substituted
- unsubstituted
- group
- Prior art date
Links
- -1 4-substituted phenoxyphenylacetic acid Chemical class 0.000 title claims 42
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims 4
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims 4
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 2
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 108010016626 Dipeptides Proteins 0.000 claims 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/04—Diamides of sulfuric acids
- C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
Claims (17)
1. Spoj opće formule (I):
[image]
ili njegova sol, naznačen time što:
R1 je Ar1-L1-W-L2-;
L2 je -(CRcRd)m,-;
W je -CONR3a- ili -NR3bCO-;
svaki od R3a i R3b je H ili metil;
L1 je -(CRaRb)n-, -(CH=CH)- ili -O(CRaRb), uz uvjet da kada je W -NR3CO-, L1 nije -(CH=CH)-;
n i m su neovisno 0, 1 ili 2;
svaki Ra, Rb, Rc i Rd je neovisno H, F, OH, metil ili ciklopropil, ili Ra i Rb ili Rc i Rd, zajedno s ugljikom na kojeg su vezani, tvore ciklopropilni prsten;
Ar1 je fenil ili naftil, od kojih je svaki nesupstituiran ili je supstituiran s jednim ili više supstituenata, koje se neovisno bira između F, Cl, CN, CF3, CHF2, CH2F, SF5, metila, etila, ciklopropila, t-butila ili OMe, ili je Ar1 1,2,3,4-tetrahidronaftil, koji je nesupstituiran ili je supstituiran s metoksi,
uz uvjet da kada je Ar1 naftil ili 1,2,3,4-tetrahidronaftil, n je 0;
R2 je H, C1-C6 alkil, aminokiselinski ostatak ili dipeptid, ili CHRe(CH2)qRf;
q je 1 do 6;
Re je H, metil ili etil;
Rf je NRgRh, u kojem Rg i Rh svaki neovisno predstavlja atom vodika ili C1-C4 alkilnu skupinu, ili Rg i Rh, zajedno s atomom dušika na kojeg su vezani, tvore 5-6-eročlani heterociklički prsten, koji izborno sadrži drugi heteroatom u prstenu, kojeg se bira između N i O, gdje je navedeni heterociklički prsten izborno supstituiran s jednom ili više skupina, koje se neovisno bira između C1-C6 alkila;
A je CN, CH2NH2, CH2NR4aC(=O)R5 ili CH2NR4bSO2R6, Cl, OMe, (1-4C)alkil, ciklopropil, H, F, Br, CH2NH(1-4C alkil), CH2N(1-4C alkil)2, tienil ili fenil, koji je nesupstituiran ili je supstituiran s SO2Me;
svaki od R4a i R4b je H ili metil;
R5 je C1-C6 alkil, C1-C6 alkoksi, C3-C6 cikloalkil, hetAr1 ili Ar2;
R6 je C1-C6 alkil, NH(C1-C6 alkil), N(C1-C6 alkil)2, Ar3 ili hetAr2;
hetAr1 je 6-eročlani heteroaril, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između atoma halogena i skupine formule -NR5aR5b, u kojoj svaki od R5a i R5b neovisno predstavlja atom vodika ili (1-4C) alkilnu skupinu, ili, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinilnu, piperidinilnu ili morfolino skupinu;
hetAr2 je 5-6-eročlani heteroaril, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između C1-C4 alkila;
Ar2 je fenil, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između atoma halogena, CN, SF5, ciklopropila, C1-C4 alkilne skupine, C1-C4 alkoksi skupine i fluorC1-C4 alkilne skupine;
Ar3 je definiran kao za Ar2;
R7 i R8 su neovisno H, metil ili F;
R9 je H ili metil; i
R10 je H ili F.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ima formulu Ia,
[image]
gdje
R1 je Ar1-L1-W-L2-;
L2 je -(CRcRd)m-;
W je -CONR3a- ili -NR3bCO-;
svaki od R3a i R3b je H ili metil;
L1 je -(CRaRb)a-, -(CH=CH)- ili -O(CRaRb)-, uz uvjet da kada je W -NR3CO-, L1 nije -(CH=CH)-;
n i m su neovisno 0, 1 ili 2;
svaki Ra, Rb, Rc i Rd je neovisno H, F, metil ili ciklopropil, ili Ra i Rb ili Rc i Rd, zajedno s ugljikom na kojeg su vezani, tvore ciklopropilni prsten;
Ar1 je fenil ili naftil, od kojih je svaki nesupstituiran ili je supstituiran s jednim ili više supstituenata, koje se neovisno bira između F, Cl, CN, CF3, CHF2, CH2F, SF5, metila, etila i ciklopropila, uz uvjet da kada je Ar1 naftil, n je 0;
R2 je H, C1-C6 alkil, aminokiselinski ostatak ili dipeptid, ili CHRe(CH2)qRf;
q je 1 do 6;
Re je H, metil ili etil;
Rf je NRgRh, u kojem Rg i Rh svaki neovisno predstavlja atom vodika ili C1-C4 alkilnu skupinu, ili Rg i Rh, zajedno s atomom dušika na kojeg su vezani, tvore 5-6-eročlani heterociklički prsten, koji izborno sadrži drugi heteroatom u prstenu, kojeg se bira između N i O, gdje je navedeni heterociklički prsten izborno supstituiran s jednom ili više skupina, koje se neovisno bira između C1-C6 alkila;
A je CN, CH2NH2, CH2NR4aC(=O)R5, CH2NR4bSO2R6, Cl, OMe, (1-4C)alkil ili ciklopropil;
svaki od R4a i R4b je H ili metil;
R5 je C1-C6 alkil, C1-C6 alkoksi, C3-C6 cikloalkil, hetAr1 ili Ar2;
R6 je C1-C6 alkil, NH(C1-C6 alkil), N(C1-C6 alkil)2, Ar3 ili hetAr2;
hetAr1 je 6-eročlani heteroaril, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između atoma halogena i skupine formule -NR5aR5b, u kojoj svaki od R5a i R5b neovisno predstavlja atom vodika ili (1-4C) alkilnu skupinu, ili, zajedno s atomom dušika na kojeg su vezani, tvore pirolidinilnu, piperidinilnu ili morfolino skupinu;
hetAr2 je 5-6-eročlani heteroaril, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između C1-C4 alkila;
Ar2 je fenil, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se neovisno bira između atoma halogena, CN, SF5, ciklopropila, C1-C4 alkilne skupine, C1-C4 alkoksi skupine i fluorC1-C4 alkilne skupine;
Ar3 je definiran kao za Ar2; i
R7 i R8 su neovisno H ili metil.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se -L1-W-L2- bira između -CONH-, -CH2CONH-, -CH2CH2CONH-, -CONHCH2-, -CH2CONHCH2-, -NHCO-, -CH2NHCO-, -NHCOCH2-, -CH2CH2NHCO-, -CH2NHCOCH2-, -CH2CH2NHCOCH2-, -CH2N(CH)COCH2-, ciklopropilidenCH2NHCO, -CH2ONHCO-, -CH(OH)CH2NHCO- i -ciklopropilidinNHCO-.
4. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 3, naznačen time što je Ar1 naftilna skupina ili fenilna skupina, koja je nesupstituirana ili je supstituirana s jednim ili dva supstituenta, koje se neovisno bira između F, Cl, CF3, OMe, Me i t-Bu ili 1,2,3,4-tetrahidronaftilne skupine, koja je nesupstituirana ili je supstituirana s OMe.
5. Spoj u skladu s patentnim zahtjevom 4, naznačen time što je Ar1 naftil, fenil, 4-fluorfenil, 3,4-difluorfenil, 2-klorfenil, 3-klorfenil, 4-klorfenil, 3,4-diklorfenil, 4-klor-3-fluorfenil, 3-klor-4-fluorfenil, 4-trifluormetilfenil, 3-fluor-4-fluormetilfenil, 3-trifluormetilfenil, 2,6-diklorfenil, 2,4-diklorfenil, 3-metoksifenil, 4-metoksifenil, 4-tertbutilfenil, 3-fluorfenil i 4-metilfenil, 1,2,3,4-tetrahidronaft-2-il ili 6-metoksi-1,2,3,4-tetrahidronaft-2-il.
6. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je 6-eročlana heteroarilna skupina u hetAr1 piridilna skupina, a 5-6-eročlani heteroaril u hetAr2 je imidazolilna ili piridilna skupina.
7. Spoj u skladu s patentnim zahtjevom 6, naznačen time što je R5 C1-C6 alkil; C1-C6, alkoksi; C3-C6 cikloalkil; piridil, koji je nesupstituiran ili je supstituiran s atomom halogena ili skupinom formule -NR5aR5b, u kojoj svaki od R5a i R5b neovisno predstavlja atom vodika ili (1-4C) alkilnu skupinu, ili, zajedno s atomom dušika na gojeg su vezani, tvore pirolidinilnu, piperidinilnu ili morfolino skupinu; ili fenilna skupina, koja je nesupstituirana ili je supstituirana s jednim ili dva atoma halogena, a R6 je C1-C6 alkil, NH(C1-C6 alkil), N(C1-C6 alkil)2, fenilna skupina, koja je nesupstituirana ili je supstituirana s jednim ili dva atoma halogena, piridil ili imidazolil, koji je nesupstituiran ili je supstituiran s C1-C3 alkilnom skupinom.
8. Spoj u skladu s patentnim zahtjevom 7, naznačen time što je R5 metil, metoksi, cikloheksil, pirid-2-il, pirid-3-il, pirid-4-il, 6-klorpirid-3-il, 6-aminopirid-3-il, 6-pirolidin-1-ilpirid-3-il ili 4-fluorfenil, a R6 je metil, dimetilamino, 4-fluorfenil, 2,4-diklorfenil, pirid-3-il, 1-metilimidazol-5-il ili 6-dimetilaminopirid-3-il.
9. Spoj u skladu s patentnim zahtjevima 1 ili 3-5, naznačen time što se A bira između cijano, acetamidometila, cikloheksilamidometila, metoksikarbonilaminometila, pikolinamidometila, nikotinamidometila, izonikotinamidometila, 6-klorpirid-3-ilamidometila, 6-aminopirid-3-ilamidometila, 6-pirolidin-1-ilpirid-3-ilamidometila, 4-fluorbenzamidometila, metilsulfonamidometila, N,N-dimetilsulfamoilamino, 4-fluorfenilsulfonamidometila, 2,4-diklorfenilsulfononamidometila, 1-metilimidazol-5-ilsulfonamidometila, pirid-3-ilsulfonamidometila, 6-dimetilaminopirid-3-ilamidometila, 2-(4-fluorfenilsulfonamido)acetamidometila, dimetilaminometil, (N-metilmetilsulfonamido)metil, H, F, Br, Cl, metila, etila, ciklopropila, CH2NH2, CH2NMe2, tienila, fenila, 3-metilsulfonilfenila i 4-metilsulfonilfenila.
10. Spoj u skladu s patentnim zahtjevom 9, naznačen time što se A bira između cijano, acetamidometila, cikloheksilamidometila, metoksikarbonilaminometila, pikolinamidometila, nikotinamidometila, izonikotinamidometila, 4-fluorbenzamidometila, metilsulfonamidometila, N,N-dimetilsulfamoilamino, 4-fluorfenilsulfonamidometila, 2,4-diklorfenilsulfonamidometila, pirid-3-ilsulfonamidometila, 6-dimetilaminopirid-3-ilamidometila, 2-(4-fluorfenilsulfonamido)acetamidometila, dimetilaminometila, (N-metilmetilsulfonamido)metila, H, F, Br, Cl, metila, etila, ciklopropila, CH2NH2, CH2NMe2, tienila, SO2Me, fenila, 3-metilsulfonilfenila i 4-metilsulfonilfenila.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što R2 je vodik.
12. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što R7 i R8 su H.
13. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 3-12, naznačen time što R9 je H.
14. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 ili 3-13, naznačen time što R10 je H.
15. Farmaceutski pripravak, naznačen time što sadrži spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili njegovu farmaceutski prihvatljivu sol, te farmaceutski prihvatljiv razrjeđivač ili podlogu.
16. Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
17. Upotreba spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili njegove farmaceutski prihvatljive soli, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje imunološkog poremećaja.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83901806P | 2006-08-21 | 2006-08-21 | |
US85138506P | 2006-10-13 | 2006-10-13 | |
PCT/US2007/076378 WO2008024746A1 (en) | 2006-08-21 | 2007-08-21 | 4-substituted phenoxyphenylacetic acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20130004T1 true HRP20130004T1 (hr) | 2013-01-31 |
HRP20130004T8 HRP20130004T8 (en) | 2013-03-31 |
Family
ID=38904570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130004TT HRP20130004T8 (en) | 2006-08-21 | 2013-01-03 | 4-substituted phenoxyphenylacetic acid derivatives |
Country Status (25)
Country | Link |
---|---|
US (2) | US8183289B2 (hr) |
EP (1) | EP2057115B9 (hr) |
JP (1) | JP5582634B2 (hr) |
KR (1) | KR101397352B1 (hr) |
CN (1) | CN101553461A (hr) |
AU (1) | AU2007286829B2 (hr) |
BR (1) | BRPI0715617A2 (hr) |
CA (1) | CA2661164C (hr) |
CO (1) | CO6160224A2 (hr) |
DK (1) | DK2057115T3 (hr) |
ES (1) | ES2396715T3 (hr) |
HR (1) | HRP20130004T8 (hr) |
IL (1) | IL197135A (hr) |
MX (1) | MX2009001876A (hr) |
MY (1) | MY149934A (hr) |
NZ (1) | NZ575507A (hr) |
PL (1) | PL2057115T3 (hr) |
PT (1) | PT2057115E (hr) |
RS (1) | RS52627B (hr) |
RU (1) | RU2463292C2 (hr) |
SG (1) | SG174069A1 (hr) |
SI (1) | SI2057115T1 (hr) |
TW (1) | TWI409247B (hr) |
UA (1) | UA96459C2 (hr) |
WO (1) | WO2008024746A1 (hr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA96459C2 (uk) * | 2006-08-21 | 2011-11-10 | Еррей Біофарма Інк. | 4-заміщені похідні феноксифенілоцтової кислоти |
US20090023731A1 (en) * | 2007-03-22 | 2009-01-22 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
US8362056B2 (en) * | 2007-11-05 | 2013-01-29 | Array Biopharma Inc. | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives |
KR101235961B1 (ko) | 2008-02-01 | 2013-02-21 | 판미라 파마슈티칼스, 엘엘씨 | 프로스타글란딘 d2 수용체의 n,n-이치환 아미노알킬비페닐 길항제 |
EP2257536A4 (en) * | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
JP2011518130A (ja) | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト |
NZ590437A (en) | 2008-06-25 | 2012-07-27 | Array Biopharma Inc | 6-substituted phenoxychroman carboxylic acid derivatives |
US20110144160A1 (en) | 2008-07-03 | 2011-06-16 | Amira Pharmaceuticals, Inc. | Antagonists of Prostaglandin D2 Receptors |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
EP2379535B1 (en) | 2008-12-22 | 2016-06-15 | Array Biopharma Inc. | 7-phenoxychroman carboxylic acid derivatives |
WO2010094956A1 (en) | 2009-02-17 | 2010-08-26 | Pulmagen Therapeutics (Inflammation) Limited. | Triazolopyridine derivatives as p38 map kinase inhibitors |
JP2013500978A (ja) | 2009-07-31 | 2013-01-10 | パンミラ ファーマシューティカルズ,エルエルシー. | Dp2受容体アンタゴニストの眼の医薬組成物 |
US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
JP2013516475A (ja) * | 2010-01-06 | 2013-05-13 | アミラ ファーマシューティカルズ,インク. | Dp2アンタゴニストおよびその使用 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
US20140328861A1 (en) | 2011-12-16 | 2014-11-06 | Atopix Therapeutics Limited | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis |
CN104016878B (zh) * | 2014-06-24 | 2015-06-10 | 中国药科大学 | 芳基乙酸类衍生物、其制备方法及其医药用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1266000A (en) * | 1998-11-04 | 2000-05-22 | Basf Aktiengesellschaft | 2-phenoxyphenylacetic acid derivatives, method and intermediate products for theproduction thereof, their use, and agents containing the same for combating fun gicidal pests |
JP2001072653A (ja) * | 1999-07-01 | 2001-03-21 | Taisho Pharmaceut Co Ltd | アミノ安息香酸誘導体 |
GB0015205D0 (en) * | 2000-06-21 | 2000-08-09 | Karobio Ab | Bioisosteric thyroid receptor ligands and method |
JP2002193800A (ja) * | 2000-12-22 | 2002-07-10 | Taisho Pharmaceut Co Ltd | Vegf受容体拮抗剤 |
AU2003241836A1 (en) * | 2002-10-03 | 2004-04-23 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
ZA200505523B (en) * | 2002-12-20 | 2006-09-27 | Amgen Inc | Asthma and allergic inflammation modulators |
US7557143B2 (en) * | 2003-04-18 | 2009-07-07 | Bristol-Myers Squibb Company | Thyroid receptor ligands |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
EP1773797A2 (en) * | 2004-08-06 | 2007-04-18 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds |
CN101490024A (zh) | 2006-06-09 | 2009-07-22 | Icos股份有限公司 | 用作dp-2拮抗剂的取代的苯乙酸 |
UA96459C2 (uk) * | 2006-08-21 | 2011-11-10 | Еррей Біофарма Інк. | 4-заміщені похідні феноксифенілоцтової кислоти |
-
2007
- 2007-08-21 UA UAA200902429A patent/UA96459C2/uk unknown
- 2007-08-21 RU RU2009110183/04A patent/RU2463292C2/ru not_active IP Right Cessation
- 2007-08-21 NZ NZ575507A patent/NZ575507A/en not_active IP Right Cessation
- 2007-08-21 PT PT78142940T patent/PT2057115E/pt unknown
- 2007-08-21 TW TW096130898A patent/TWI409247B/zh not_active IP Right Cessation
- 2007-08-21 WO PCT/US2007/076378 patent/WO2008024746A1/en active Application Filing
- 2007-08-21 RS RS20120563A patent/RS52627B/en unknown
- 2007-08-21 MX MX2009001876A patent/MX2009001876A/es active IP Right Grant
- 2007-08-21 SG SG2011057858A patent/SG174069A1/en unknown
- 2007-08-21 PL PL07814294T patent/PL2057115T3/pl unknown
- 2007-08-21 DK DK07814294.0T patent/DK2057115T3/da active
- 2007-08-21 EP EP07814294A patent/EP2057115B9/en active Active
- 2007-08-21 MY MYPI20090706A patent/MY149934A/en unknown
- 2007-08-21 CN CNA200780039235XA patent/CN101553461A/zh active Pending
- 2007-08-21 JP JP2009525728A patent/JP5582634B2/ja not_active Expired - Fee Related
- 2007-08-21 US US12/438,112 patent/US8183289B2/en not_active Expired - Fee Related
- 2007-08-21 KR KR1020097005733A patent/KR101397352B1/ko not_active IP Right Cessation
- 2007-08-21 BR BRPI0715617-0A2A patent/BRPI0715617A2/pt not_active IP Right Cessation
- 2007-08-21 CA CA2661164A patent/CA2661164C/en not_active Expired - Fee Related
- 2007-08-21 AU AU2007286829A patent/AU2007286829B2/en not_active Ceased
- 2007-08-21 SI SI200731117T patent/SI2057115T1/sl unknown
- 2007-08-21 ES ES07814294T patent/ES2396715T3/es active Active
-
2009
- 2009-02-19 IL IL197135A patent/IL197135A/en active IP Right Grant
- 2009-03-12 CO CO09025722A patent/CO6160224A2/es unknown
-
2012
- 2012-04-17 US US13/448,689 patent/US8492437B2/en not_active Expired - Fee Related
-
2013
- 2013-01-03 HR HRP20130004TT patent/HRP20130004T8/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130004T1 (hr) | 4-supstituirani derivati fenoksifeniloctene kiseline | |
RU2397168C2 (ru) | Производные тиофена в качестве ингибиторов снк 1 | |
RU2019131111A (ru) | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ | |
HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
HUP0203448A2 (hu) | Monoamin újrafelvétel inhibitorként alkalmazható új biaril-éter származékok és ezeket tartalmazó gyógyszerkészítmények | |
RU2005117783A (ru) | 1, 5-диарилпиррол-3-карбоксамидные производные и их применение в качестве модуляторов каннабиноидных рецепторов | |
HUP0401783A2 (hu) | 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC-kemokin receptor ligandumok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HRP20020264B1 (hr) | 2'-supstituirani 1,1'-bifenil-2-karbonamidi, postupci za njihovu proizvodnju, njihova upotreba kao lijeka, kao i farmaceutski pripravci koji ih sadrže | |
HRP20140611T1 (hr) | Inhibitori kinaze p70 s6 | |
NO20080186L (no) | Heterosykliske aspartylproteaseinhibitorer, fremstilling og anvendelse derav | |
AR036158A1 (es) | Compuestos heterobiciclicos sustituidos con triamida | |
AR049739A1 (es) | Derivados de aril-piridina | |
EP1714961A4 (en) | INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE | |
WO2003033472A1 (fr) | Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes | |
MY138906A (en) | Phenyl derivatives as ppar agonists | |
TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
YU40998A (sh) | Derivati supstituisanog 1,2,3,4-tetrahidronaftalina | |
HRP20110400T1 (hr) | Derivati 2-(1h-indolilsulfanil)-benzil amina kao ssri | |
PE20030332A1 (es) | Terapia de combinacion para el tratamiento del cancer | |
TW200635896A (en) | N-(heteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic application thereof | |
RU2016137356A (ru) | Соединение нафтиламида, способ его получения и применение | |
WO2005095399A3 (fr) | Derives pyrrolo (2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases | |
HUP0401883A2 (hu) | Muszkarin agonisták és ezeket tartalmazó gyógyászati készítmények | |
RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
CA2104456A1 (en) | Pyridine- and Imidazole-Derived Agents for Cardiovascular Diseases |